NCT06556914 Effect of Albumin Replacement on Oxygen Delivery in Sepsis Patients
| NCT ID | NCT06556914 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsun University |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-11-15 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 45 participants in total. It began in 2024-11-15 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fluid resuscitation is a critical component of sepsis treatment. Research has shown that intravenous (IV) fluid therapy in sepsis positively impacts cardiac output and thereby oxygen (O2) delivery through a complex interaction of central venous pressure, right atrial pressure, venous resistance, ventricular compliance, cardiac contractility, and systemic vascular resistance. The 2021 sepsis prevention guidelines recommend balanced crystalloids as first-line therapy. However, no studies in the literature have evaluated the effect of albumin on O2 delivery. In our study, the investigators aim to assess the impact of albumin replacement on O2 delivery in sepsis patients in the intensive care unit.
Eligibility Criteria
Inclusion Criteria: * Followed up with a diagnosis of sepsis, * over 18 years old * Patients who were diagnosed with hypo-albuminemia after more than 4L/day fluid resuscitation and underwent albumin replacement Exclusion Criteria: * Consent is not given by the patient or his/her guardian, * The initial cause of shock was hypovolemic, cardiogenic or obstructive shock. * Pregnancy or suspected pregnancy * Peripheral limb or severe organ ischemia with peripheral artery disease * Cardiac functions cannot be evaluated optimally by transthoracic echocardiography * Patients who died within the first 24 hours after intensive care admission
Contact & Investigator
gamze MD ertaş, specialist
PRINCIPAL INVESTIGATOR
Samsun University
Frequently Asked Questions
Who can join the NCT06556914 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06556914 currently recruiting?
Yes, NCT06556914 is actively recruiting participants. Contact the research team at gamzeertas555@gmail.com for enrollment information.
Where is the NCT06556914 trial being conducted?
This trial is being conducted at Samsun, Turkey (Türkiye).
Who is sponsoring the NCT06556914 clinical trial?
NCT06556914 is sponsored by Samsun University. The principal investigator is gamze MD ertaş, specialist at Samsun University. The trial plans to enroll 45 participants.